Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Post by Ingiboyon Oct 17, 2023 10:24am
147 Views
Post# 35687029

What Now ?

What Now ?This is not time to panic and sell your shares for nothing.
Firstly by today's trading activity the market baked in a Replicel loss of the Arbitration and has peged it's current value at $.10.  Let's hope so.
 
 Metzger is right there is a reason that Shiseido fought hard to retain this technology in Asia. I would assume now that they have the green light they will pursue commercialization of this hair treatment. If they do it will obviously bring value to Replicel holding the rights to the treatment for the rest of the world. In fact Shiseido may now make an offer to Replicel for those rights.

It is now time for Mainpointe to step up and honor their contract and get the Dermal Injector FDA Approval. Replicel should now quickly put all available resources toward finding a North American manufacturer of the device.

Now that we have this "cloud" which has been sitting over this company for the past 2 years lifted it is time for the management to get back to communicating with the shareholders.  I well crafted update would be very timely right about now.

<< Previous
Bullboard Posts
Next >>